Pharmacokinetics, Safety, and Tolerability Study of Multiple Oral Doses of Verducatib for 4 Weeks in Healthy Chinese Male and Female Trial Participants (Open-label, Single Arm)
Latest Information Update: 21 Apr 2026
At a glance
- Drugs Verducatib (Primary)
- Indications Bronchiectasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 21 Apr 2026 New trial record